Novel Psychoactive Substances

October 7, 2024 | Controlled Substances, Fact Sheets, Fentanyl, Novel Psychoactive Substances, Opioids, Substance Abuse

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) discusses the emergence of  "tusi," which is also known as pink cocaine. Tusi is a group of psychedelic drugs common amongst clubgoers, dyed pink, that actually rarely contains cocaine. While tusi itself is not controlled under the Controlled Substances Act, its individual components like ketamine and fentanyl often are, and because users rarely know what is in the particular mix they are ingesting, they cannot anticipate the side effects....

July 12, 2024 | Fact Sheets, Medication Assisted Treatment (MAT), Novel Psychoactive Substances, Opioids, Recovery, Substance Abuse, Treatments

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) details the changes to the "primary diagnosis other than OUD" regulation. The fact sheet also covers the federal regulatory scheme for methadone for OUD and explains what led SAMHSA to revise its regulations. ...

March 18, 2024 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the streets of the United States. This fact sheet, which focuses on Xylazine, was originally the second in a series that highlights these dangerous drugs. This is an update to the original version....

October 31, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the sixth in a series highlighting these dangerous drugs, is an examination of bromazolam....

September 18, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the fifth in a series highlighting these dangerous drugs, is an examination of nitazenes....

June 6, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) is monitoring the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the fourth in a series highlighting these potentially dangerous drugs, examines isotonitazene, a synthetic opioid recently classified as a Schedule I controlled substance under the federal Controlled Substances Act....

January 6, 2023 | Controlled Substances, Fact Sheets, Fentanyl, Kratom, Marijuana, Methamphetamine, Novel Psychoactive Substances, Opioids, Prescription Drugs, Stimulants, Substance Abuse, Synthetic Drugs

Millions of people throughout the world use social media platforms (or “apps”) providing an easy avenue to reach a large number of people. Legitimate businesses are not the only ones to use social media apps as a marketing tool. In recent years, drug dealers have turned to such apps to solicit buyers and arrange sales. This fact sheet examines the growing use of social media, by drug suppliers, to surreptitiously advertise to a wide audience, by using apps that offer encrypted or disappearing messages....